Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BRQ4
UPID:
CF300_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BRQ4; E9PJU1
Background:
Cilia- and flagella-associated protein 300 plays a pivotal role in the structural organization and motility of cilia and flagella. This protein is essential for the proper assembly of outer and inner dynein arms, which are crucial for the movement of these cellular structures.
Therapeutic significance:
Given its critical role in ciliary function, mutations in the gene encoding Cilia- and flagella-associated protein 300 lead to primary ciliary dyskinesia, particularly CILD38. This condition is marked by chronic respiratory infections and may include features such as situs inversus, underlining the protein's potential as a target for therapeutic intervention.